Jim Faulkner, former vice president for manufacturing and supply at the rare diseases unit of GlaxoSmithKline Plc, has been named head of manufacturing at Autolus Ltd, a new UK company which is developing engineered T cell immunotherapy products. Concurrently Louise Holliday, a former partner at D Young and Co LLP, has been appointed head of intellectual property. Dr Holliday specialises in all types of biotech patent work including molecular immunology, antibodies, vaccines and stem cells. She holds an MA in biochemistry from New College, Oxford and a PhD in molecular immunology from University College London.
Dr Faulkner received a BSc in biotechnology from Leeds University and a PhD in molecular biology in association with the University of Kent.
Autolus announced the appointments on 7 July 2015.
Copyright 2015 Evernow Publishing Ltd